Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-TCR-alphabeta monoclonal antibody R73

Drug Profile

Anti-TCR-alphabeta monoclonal antibody R73

Alternative Names: Alpha-beta-TCR monoclonal antibody R73; Anti-T-cell-receptor-alphabeta antibody R73; Anti-T-cell-receptor-alphabeta monoclonal antibody R73; Anti-TCR-alphabeta antibody R73; Monoclonal antibody R73; R73

Latest Information Update: 03 Jul 2002

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unknown
  • Developer Aventis Behring LLC; Nonindustrial source
  • Class Monoclonal antibodies
  • Mechanism of Action T-cell receptor antigen alpha-beta antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Transplant rejection

Most Recent Events

  • 24 Dec 1999 Hoechst has merged with Rhône-Poulenc to form Aventis
  • 09 Jul 1998 A preclincial study has been added to the pharmacodynamics section
  • 04 Sep 1996 A study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top